XM levert geen diensten aan inwoners van de Verenigde Staten.

XM levert geen diensten aan inwoners van de Verenigde Staten.
B
B

Biogen

Nieuws

Reuters - 8 uur geleden

Novo owner backs Swiss biotech Asceneuron in $100 million round

Novo owner backs Swiss biotech Asceneuron in $100 million round By Maggie Fick LONDON, July 16 (Reuters) - Swiss biotech company Asceneuron said on Tuesday it had raised $100 million from investors including the controlling shareholder of Wegovy maker Novo Nordisk to fund clinical development of its Alzheimer's disease drug. The Series C round was led by Novo Holdings, the investment arm of the Novo Nordisk Foundation, which will hold a board seat on the Lausanne-based company.
B
Reuters - 19 uur geleden

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Charter Communications Inc CHTR.OQ +4.1% Baker Hughes Co BKR.OQ +4% Fastenal Co FAST.OQ +3.9% Diamondback Energy Inc FANG.OQ +3.7% Paychex Inc PAYX.OQ +2.7% Bottom Performers Percent Change Dollar Tree Inc DLTR.OQ -3.4% Biogen Inc BIIB.OQ -3.4% PDD Holdings Inc PDD.OQ -2.8% Lululemon Athletica Inc LULU.OQ -2.7% Starbucks Corp SBUX.OQ -2.5% The Nasdaq 100 .NDX gained 39.49 points,
B
C
F
L
P
S
D
U
D
P
Reuters - 23 uur geleden

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +4.8% Baker Hughes Co BKR.OQ +4.4% Charter Communications Inc CHTR.OQ +3.7% Old Dominion Freight Line Inc ODFL.OQ +3.4% Fastenal Co FAST.OQ +3.3% Bottom Performers Percent Change PDD Holdings Inc PDD.OQ -2.4% Dollar Tree Inc DLTR.OQ -2.3% Xcel Energy Inc XEL.OQ -2.1% Ross Stores Inc ROST.OQ -1.9% Biogen Inc BIIB.OQ -1.9% The Nasdaq 100 .NDX gained 163.39 points,
B
C
F
T
X
D
R
U
P
O
Reuters - 4 dagen geleden

U.S. STOCKS Deckers Outdoor, Amgen, BlackRock

BUZZ-U.S. STOCKS ON THE MOVE-Deckers Outdoor, Amgen, BlackRock Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Dow touched a record high on Friday as this year's lagging stocks gained favor on optimism that the U.S. Federal Reserve will begin easing monetary policy in September, while big lenders fell after reporting mixed results.
A
A
B
C
I
J
T
R
U
U
E
T
Reuters - 4 dagen geleden

Piper Sandler cuts Biogen's PT expecting tepid uptake for Alzheimer's drug Leqembi

BUZZ-Piper Sandler cuts Biogen's PT expecting tepid uptake for Alzheimer's drug Leqembi Updates ** Shares of B iogen BIIB.O down more than 4% to ~$227 in afternoon trading * * Brokerage Piper Sandler cuts B iogen's stock PT to $313 from $335, slashing its near- and long-term sales outlook for co's Alzheimer's disease (AD) drug, Leqembi ** Says its new April-June survey data indicates Leqembi continues to face meaningful uptake barriers and doctors indicate relatively tepid uptake dynamics ** Mor
B
Reuters - 4 dagen geleden

U.S. STOCKS Estee Lauder, Deckers Outdoor, Amgen

BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, Deckers Outdoor, Amgen Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes rose on Friday as slightly hotter-than-expected producer price numbers did little to change bets around a U.S.
A
A
B
C
J
T
R
U
U
E
T
Reuters - 4 dagen geleden

U.S. STOCKS U.S. banks, Tesla, Snowflake

BUZZ-U.S. STOCKS ON THE MOVE-U.S. banks, Tesla, Snowflake Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was set for a subdued open on Friday as investors digested mixed results from big banks, while slightly hotter-than-expected producer price numbers reined in bets that the Federal Reserve would begin easing interest rates in September.
A
B
C
J
T
R
U
T
Reuters - 4 dagen geleden

U.S. STOCKS Tesla, Teck Resources, JPMorgan

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Teck Resources, JPMorgan Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. index futures struggled for direction on Friday as investors parsed a set of big bank earnings to gauge the health of corporate America, while awaiting key inflation data for clues on the timing of interest rate cuts.
B
B
J
T
R
U
T
Reuters - 4 dagen geleden

Piper Sandler cuts Biogen's PT expecting tepid uptake for Alzheimer's drug Leqembi

BUZZ-Piper Sandler cuts Biogen's PT expecting tepid uptake for Alzheimer's drug Leqembi ** Brokerage Piper Sandler cuts Biogen's BIIB.O stock PT to $313 from $335, slashing its near- and long-term sales outlook for co's Alzheimer's disease (AD) drug, Leqembi ** Says its new April-June survey data indicates Leqembi continues to face meaningful uptake barriers and doctors indicate relatively tepid uptake dynamics ** More than halves FY'25 sales est.
B
Reuters - 2 weken geleden

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +6.5% NVIDIA Corp NVDA.OQ +4.6% Broadcom Inc AVGO.OQ +4.3% Micron Technology Inc MU.OQ +3.2% Arm Holdings PLC ARM.OQ +2.9% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Gilead Sciences Inc GILD.OQ -2.6% Regeneron Pharmaceuticals Inc REGN.OQ -2.0% Biogen Inc BIIB.OQ -1.8% O'Reilly Automotive Inc ORLY.OQ -1.6% The Nasdaq 100 .NDX gained
B
B
G
M
N
R
T
W
U
Reuters - 2 weken geleden

Street View: Eli Lilly's Alzheimer's drug approval likely to also benefit Biogen

BUZZ-Street View: Eli Lilly's Alzheimer's drug approval likely to also benefit Biogen ** The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's LLY.N treatment for early Alzheimer's under the brand name Kisunla, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S. patients *
B
Reuters - 2 weken geleden

Eli Lilly Alzheimer's drug approved by US FDA

UPDATE 3-Eli Lilly Alzheimer's drug approved by US FDA Adds Leqembi comparison, expert and analyst comments in paragraphs 5-16 By Julie Steenhuysen and Mariam Sunny July 2 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's LLY.N treatment for early Alzheimer's, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S.
B
Reuters - 2 weken geleden

Japan's Eisai developing dementia drug for US market, Nikkei reports

Japan's Eisai developing dementia drug for US market, Nikkei reports TOKYO, June 30 (Reuters) - Japanese drugmaker Eisai 4523.T is developing a d ementia treatment that it aims to commerciali s e in the U.S. by fiscal 2030, the Nikke i r eported on Sunday. The new drug targets a protein called tau, which causes symptoms of Alzheimer's disease, the newspaper reported.
B
Reuters - 3 weken geleden

Eisai and Biogen launch Alzheimer's drug Leqembi in China

Eisai and Biogen launch Alzheimer's drug Leqembi in China June 28 (Reuters) - Eisai 4523.T and Biogen BIOAb.ST have launched their Alzheimer's treatment Leqembi in China, the third country after the United States and Japan, the companies said on Friday. Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease.
B
Reuters - 3 weken geleden

Biogen has up to $10 billion for its next M&A bets- Bloomberg News

MEDIA-Biogen has up to $10 billion for its next M&A bets- Bloomberg News -- Source link: https://tinyurl.com/3w57zmcr -- Note: Reuters has not verified this story and does not vouch for its accuracy
B
Reuters - 3 weken geleden

Tofidence A Biosimilar Referencing Roactemra, Approved In The European Union

BRIEF-Tofidence A Biosimilar Referencing Roactemra, Approved In The European Union June 24 (Reuters) - Biogen Inc BIIB.O : TOFIDENCE™ (TOCILIZUMAB), A BIOSIMILAR REFERENCING ROACTEMRA®, APPROVED IN THE EUROPEAN UNION Source text for Eikon: ID:nGNE95yLRY Further company coverage: BIIB.O
B
Reuters - 4 weken geleden

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Autodesk Inc ADSK.OQ +6.8% Tesla Inc TSLA.OQ +5.8% Broadcom Inc AVGO.OQ +5.7% Micron Technology Inc MU.OQ +4.7% Synopsys Inc SNPS.OQ +4.0% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -3.2% Atlassian Corp TEAM.OQ -2.4% Biogen Inc BIIB.OQ -2.2% ON Semiconductor Corp ON.OQ -2.0% Marvell Technology Inc MRVL.OQ -1.8% The Nasdaq 100 .NDX gained 287.51 points, or
A
B
B
M
M
T
W
O
U
A
S
Reuters - 1 maand geleden

About 4% of US adults age 65 and older have a dementia diagnosis, survey finds

About 4% of US adults age 65 and older have a dementia diagnosis, survey finds By Christy Santhosh June 13(Reuters) - Some 4% of U.S. adults aged 65 and older say they have been diagnosed with dementia, a rate that reached 13% for those at least 85-years old, according to a report of a national survey released on Thursday. The report issued by the U.S.
B
Reuters - 1 maand geleden

Biogen executive plays down looming competition for its Alzheimer's drug

UPDATE 1-Biogen executive plays down looming competition for its Alzheimer's drug Adds executive comments in paragraphs 3-4, analysts' comments in paragraphs 9-11 By Sriparna Roy June 12 (Reuters) - Biogen's BIIB.O Alzheimer's drug, Leqembi, will do well in the market whether a competitor comes or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday.
B
G
Reuters - 1 maand geleden

Biogen executive says its Alzheimer's drug will do well in market despite competition

Biogen executive says its Alzheimer's drug will do well in market despite competition June 12 (Reuters) - Biogen's BIIB.O Alzheimer's drug, Leqembi, will do well in the market, whether a competitor will come or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editi
B

Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.